nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—Retinoids—Tretinoin—peripheral nervous system neoplasm	0.147	0.5	CiPCiCtD
Alitretinoin—Retinoids—Isotretinoin—peripheral nervous system neoplasm	0.147	0.5	CiPCiCtD
Alitretinoin—Isotretinoin—peripheral nervous system neoplasm	0.127	0.5	CrCtD
Alitretinoin—Tretinoin—peripheral nervous system neoplasm	0.127	0.5	CrCtD
Alitretinoin—ABCB1—peripheral nervous system neoplasm	0.0374	1	CbGaD
Alitretinoin—Isotretinoin—Tretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—Tretinoin—Isotretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—Vitamin A—Isotretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—Vitamin A—Tretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—Acitretin—Isotretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—Acitretin—Tretinoin—peripheral nervous system neoplasm	0.0273	0.167	CrCrCtD
Alitretinoin—CRABP1—Tretinoin—peripheral nervous system neoplasm	0.0228	0.119	CbGbCtD
Alitretinoin—CRABP2—Tretinoin—peripheral nervous system neoplasm	0.0228	0.119	CbGbCtD
Alitretinoin—RXRG—Isotretinoin—peripheral nervous system neoplasm	0.0165	0.0861	CbGbCtD
Alitretinoin—RARG—Isotretinoin—peripheral nervous system neoplasm	0.0165	0.0861	CbGbCtD
Alitretinoin—RARA—Isotretinoin—peripheral nervous system neoplasm	0.0146	0.0761	CbGbCtD
Alitretinoin—RXRB—Isotretinoin—peripheral nervous system neoplasm	0.0146	0.0761	CbGbCtD
Alitretinoin—RXRA—Isotretinoin—peripheral nervous system neoplasm	0.0146	0.0761	CbGbCtD
Alitretinoin—RARB—Isotretinoin—peripheral nervous system neoplasm	0.0146	0.0761	CbGbCtD
Alitretinoin—RARG—Tretinoin—peripheral nervous system neoplasm	0.00948	0.0495	CbGbCtD
Alitretinoin—RXRG—Tretinoin—peripheral nervous system neoplasm	0.00948	0.0495	CbGbCtD
Alitretinoin—RXRA—Tretinoin—peripheral nervous system neoplasm	0.00838	0.0437	CbGbCtD
Alitretinoin—RXRB—Tretinoin—peripheral nervous system neoplasm	0.00838	0.0437	CbGbCtD
Alitretinoin—RARB—Tretinoin—peripheral nervous system neoplasm	0.00838	0.0437	CbGbCtD
Alitretinoin—RARA—Tretinoin—peripheral nervous system neoplasm	0.00838	0.0437	CbGbCtD
Alitretinoin—ABCB1—Topotecan—peripheral nervous system neoplasm	0.000482	0.00252	CbGbCtD
Alitretinoin—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.000441	0.0023	CbGbCtD
Alitretinoin—RXRA—ganglion—peripheral nervous system neoplasm	0.000355	0.175	CbGeAlD
Alitretinoin—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.000334	0.00174	CbGbCtD
Alitretinoin—RARG—tongue—peripheral nervous system neoplasm	0.000258	0.127	CbGeAlD
Alitretinoin—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.000216	0.00113	CbGbCtD
Alitretinoin—ABCB1—Vincristine—peripheral nervous system neoplasm	0.000206	0.00107	CbGbCtD
Alitretinoin—CRABP1—trigeminal ganglion—peripheral nervous system neoplasm	0.000194	0.0953	CbGeAlD
Alitretinoin—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.000192	0.001	CbGbCtD
Alitretinoin—ABCB1—Etoposide—peripheral nervous system neoplasm	0.000189	0.000984	CbGbCtD
Alitretinoin—CRABP2—trigeminal ganglion—peripheral nervous system neoplasm	0.000175	0.0862	CbGeAlD
Alitretinoin—CRABP1—brainstem—peripheral nervous system neoplasm	0.000171	0.0844	CbGeAlD
Alitretinoin—CRABP2—parotid gland—peripheral nervous system neoplasm	0.000165	0.0813	CbGeAlD
Alitretinoin—RXRG—trigeminal ganglion—peripheral nervous system neoplasm	0.000153	0.0754	CbGeAlD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000129	0.0466	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000129	0.0466	CbGpPWpGaD
Alitretinoin—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000671	CbGbCtD
Alitretinoin—RARG—trigeminal ganglion—peripheral nervous system neoplasm	0.000128	0.0629	CbGeAlD
Alitretinoin—CRABP1—The citric acid (TCA) cycle and respiratory electron transport—COX2—peripheral nervous system neoplasm	0.000101	0.0365	CbGpPWpGaD
Alitretinoin—CRABP2—The citric acid (TCA) cycle and respiratory electron transport—COX2—peripheral nervous system neoplasm	0.000101	0.0365	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.2e-05	0.0333	CbGpPWpGaD
Alitretinoin—CRABP1—cerebellum—peripheral nervous system neoplasm	8.46e-05	0.0416	CbGeAlD
Alitretinoin—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	8.25e-05	0.0298	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	7.91e-05	0.0286	CbGpPWpGaD
Alitretinoin—CRABP2—cerebellum—peripheral nervous system neoplasm	7.65e-05	0.0376	CbGeAlD
Alitretinoin—RARB—cerebellum—peripheral nervous system neoplasm	6.84e-05	0.0336	CbGeAlD
Alitretinoin—RXRB—cerebellum—peripheral nervous system neoplasm	6.28e-05	0.0309	CbGeAlD
Alitretinoin—RARG—cerebellum—peripheral nervous system neoplasm	5.58e-05	0.0274	CbGeAlD
Alitretinoin—RARA—cerebellum—peripheral nervous system neoplasm	5.24e-05	0.0258	CbGeAlD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	5.16e-05	0.0187	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—MET—peripheral nervous system neoplasm	5.15e-05	0.0186	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.13e-05	0.0185	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.13e-05	0.0185	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	4.94e-05	0.0179	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—MET—peripheral nervous system neoplasm	4.84e-05	0.0175	CbGpPWpGaD
Alitretinoin—RXRA—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	4.33e-05	0.0157	CbGpPWpGaD
Alitretinoin—RXRA—Orphan transporters—COX2—peripheral nervous system neoplasm	4.03e-05	0.0146	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	3.9e-05	0.0141	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—ERBB2—peripheral nervous system neoplasm	3.76e-05	0.0136	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—peripheral nervous system neoplasm	3.54e-05	0.0128	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.38e-05	0.0122	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.38e-05	0.0122	CbGpPWpGaD
Alitretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—COX2—peripheral nervous system neoplasm	3.06e-05	0.0111	CbGpPWpGaD
Alitretinoin—RARG—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.8e-05	0.0101	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	2.58e-05	0.00932	CbGpPWpGaD
Alitretinoin—RXRG—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.56e-05	0.00925	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	2.53e-05	0.00914	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—MET—peripheral nervous system neoplasm	2.52e-05	0.00912	CbGpPWpGaD
Alitretinoin—RARB—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.51e-05	0.00907	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	2.42e-05	0.00876	CbGpPWpGaD
Alitretinoin—RARA—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.4e-05	0.0087	CbGpPWpGaD
Alitretinoin—RXRB—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.4e-05	0.0087	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	2.3e-05	0.00833	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.28e-05	0.00826	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.28e-05	0.00826	CbGpPWpGaD
Alitretinoin—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	2.28e-05	0.0112	CbGeAlD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	2.21e-05	0.00799	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	2.11e-05	0.00763	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—peripheral nervous system neoplasm	2.09e-05	0.00758	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	2.07e-05	0.0075	CbGpPWpGaD
Alitretinoin—RXRA—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	2.03e-05	0.00733	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	2.02e-05	0.00731	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	1.99e-05	0.00719	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—EED—peripheral nervous system neoplasm	1.98e-05	0.00718	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—peripheral nervous system neoplasm	1.97e-05	0.00712	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	1.95e-05	0.00704	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.9e-05	0.00687	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.9e-05	0.00687	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—peripheral nervous system neoplasm	1.85e-05	0.00669	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—ERBB2—peripheral nervous system neoplasm	1.84e-05	0.00667	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—EED—peripheral nervous system neoplasm	1.81e-05	0.00656	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—EED—peripheral nervous system neoplasm	1.78e-05	0.00644	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—peripheral nervous system neoplasm	1.74e-05	0.00629	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—EED—peripheral nervous system neoplasm	1.71e-05	0.00617	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—EED—peripheral nervous system neoplasm	1.71e-05	0.00617	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GNS—peripheral nervous system neoplasm	1.65e-05	0.00597	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GNS—peripheral nervous system neoplasm	1.65e-05	0.00597	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	1.63e-05	0.00589	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CNTN6—peripheral nervous system neoplasm	1.59e-05	0.00575	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.59e-05	0.00574	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NME1—peripheral nervous system neoplasm	1.58e-05	0.00573	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NME1—peripheral nervous system neoplasm	1.58e-05	0.00573	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.55e-05	0.00562	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—COX2—peripheral nervous system neoplasm	1.52e-05	0.00551	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—COX2—peripheral nervous system neoplasm	1.52e-05	0.00551	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.45e-05	0.00525	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.42e-05	0.00515	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.36e-05	0.00493	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.36e-05	0.00493	CbGpPWpGaD
Alitretinoin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	1.32e-05	0.00476	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	1.26e-05	0.00457	CbGpPWpGaD
Alitretinoin—RXRA—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	1.25e-05	0.00453	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—HGF—peripheral nervous system neoplasm	1.25e-05	0.00451	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	1.23e-05	0.00444	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.16e-05	0.0042	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.15e-05	0.00416	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.11e-05	0.00403	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.05e-05	0.00381	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.05e-05	0.00381	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	1.04e-05	0.00375	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	1.03e-05	0.00372	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—peripheral nervous system neoplasm	1.03e-05	0.00371	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.02e-05	0.0037	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.01e-05	0.00365	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ENO2—peripheral nervous system neoplasm	1e-05	0.00362	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ENO2—peripheral nervous system neoplasm	1e-05	0.00362	CbGpPWpGaD
Alitretinoin—ABCB1—cerebellum—peripheral nervous system neoplasm	9.96e-06	0.0049	CbGeAlD
Alitretinoin—RXRA—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	9.85e-06	0.00356	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—peripheral nervous system neoplasm	9.06e-06	0.00328	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—EED—peripheral nervous system neoplasm	8.89e-06	0.00322	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—BCHE—peripheral nervous system neoplasm	8.45e-06	0.00306	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—BCHE—peripheral nervous system neoplasm	8.45e-06	0.00306	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	8.23e-06	0.00298	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.06e-06	0.00292	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.06e-06	0.00292	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—TH—peripheral nervous system neoplasm	7.95e-06	0.00287	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—TH—peripheral nervous system neoplasm	7.95e-06	0.00287	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	7.89e-06	0.00285	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—NCAM1—peripheral nervous system neoplasm	7.76e-06	0.00281	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—SUZ12—peripheral nervous system neoplasm	7.11e-06	0.00257	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.91e-06	0.0025	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.76e-06	0.00244	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GNAS—peripheral nervous system neoplasm	6.49e-06	0.00235	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GNAS—peripheral nervous system neoplasm	6.49e-06	0.00235	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.48e-06	0.00234	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ABCB1—peripheral nervous system neoplasm	6.37e-06	0.0023	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.37e-06	0.0023	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	5.8e-06	0.0021	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.75e-06	0.00208	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.7e-06	0.00206	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.47e-06	0.00198	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	5.26e-06	0.0019	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.21e-06	0.00189	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	5.05e-06	0.00183	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GNS—peripheral nervous system neoplasm	5e-06	0.00181	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.95e-06	0.00179	CbGpPWpGaD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	4.88e-06	0.00176	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—NME1—peripheral nervous system neoplasm	4.79e-06	0.00173	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—COX2—peripheral nervous system neoplasm	4.61e-06	0.00167	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.6e-06	0.00166	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	4.56e-06	0.00165	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.4e-06	0.00159	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.26e-06	0.00154	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.21e-06	0.00152	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.19e-06	0.00152	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	4.17e-06	0.00151	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.11e-06	0.00149	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	4.11e-06	0.00149	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	4.1e-06	0.00148	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.09e-06	0.00148	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	4.09e-06	0.00148	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	3.94e-06	0.00142	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	3.92e-06	0.00142	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	3.92e-06	0.00142	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MET—peripheral nervous system neoplasm	3.71e-06	0.00134	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—PTPN11—peripheral nervous system neoplasm	3.43e-06	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	3.38e-06	0.00122	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.27e-06	0.00118	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	3.22e-06	0.00116	CbGpPWpGaD
Alitretinoin—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	3.12e-06	5.71e-05	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	3.12e-06	5.7e-05	CcSEcCtD
Alitretinoin—Asthma—Doxorubicin—peripheral nervous system neoplasm	3.1e-06	5.67e-05	CcSEcCtD
Alitretinoin—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	3.1e-06	5.67e-05	CcSEcCtD
Alitretinoin—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	3.1e-06	5.66e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	3.09e-06	5.65e-05	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	3.06e-06	5.59e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	3.06e-06	5.59e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Etoposide—peripheral nervous system neoplasm	3.05e-06	5.58e-05	CcSEcCtD
Alitretinoin—Weight increased—Epirubicin—peripheral nervous system neoplasm	3.05e-06	5.58e-05	CcSEcCtD
Alitretinoin—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	3.04e-06	5.56e-05	CcSEcCtD
Alitretinoin—Weight decreased—Epirubicin—peripheral nervous system neoplasm	3.03e-06	5.54e-05	CcSEcCtD
Alitretinoin—Dyspnoea—Etoposide—peripheral nervous system neoplasm	3.03e-06	5.54e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—ENO2—peripheral nervous system neoplasm	3.03e-06	0.0011	CbGpPWpGaD
Alitretinoin—Somnolence—Etoposide—peripheral nervous system neoplasm	3.02e-06	5.53e-05	CcSEcCtD
Alitretinoin—Asthenia—Vincristine—peripheral nervous system neoplasm	3.01e-06	5.51e-05	CcSEcCtD
Alitretinoin—Pneumonia—Epirubicin—peripheral nervous system neoplasm	3.01e-06	5.5e-05	CcSEcCtD
Alitretinoin—Drowsiness—Epirubicin—peripheral nervous system neoplasm	2.99e-06	5.46e-05	CcSEcCtD
Alitretinoin—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	2.99e-06	5.46e-05	CcSEcCtD
Alitretinoin—Infestation—Epirubicin—peripheral nervous system neoplasm	2.99e-06	5.46e-05	CcSEcCtD
Alitretinoin—Vomiting—Dactinomycin—peripheral nervous system neoplasm	2.99e-06	5.46e-05	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	2.96e-06	5.42e-05	CcSEcCtD
Alitretinoin—Rash—Dactinomycin—peripheral nervous system neoplasm	2.96e-06	5.42e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Etoposide—peripheral nervous system neoplasm	2.96e-06	5.4e-05	CcSEcCtD
Alitretinoin—Renal failure—Epirubicin—peripheral nervous system neoplasm	2.94e-06	5.37e-05	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	2.94e-06	5.37e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	2.94e-06	5.36e-05	CcSEcCtD
Alitretinoin—Fatigue—Etoposide—peripheral nervous system neoplasm	2.93e-06	5.36e-05	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	2.93e-06	5.36e-05	CcSEcCtD
Alitretinoin—Stomatitis—Epirubicin—peripheral nervous system neoplasm	2.91e-06	5.33e-05	CcSEcCtD
Alitretinoin—Constipation—Etoposide—peripheral nervous system neoplasm	2.91e-06	5.32e-05	CcSEcCtD
Alitretinoin—Pain—Etoposide—peripheral nervous system neoplasm	2.91e-06	5.32e-05	CcSEcCtD
Alitretinoin—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	2.91e-06	5.31e-05	CcSEcCtD
Alitretinoin—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	2.91e-06	5.31e-05	CcSEcCtD
Alitretinoin—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	2.9e-06	5.3e-05	CcSEcCtD
Alitretinoin—Dysuria—Doxorubicin—peripheral nervous system neoplasm	2.9e-06	5.3e-05	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	2.88e-06	5.27e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Vincristine—peripheral nervous system neoplasm	2.87e-06	5.25e-05	CcSEcCtD
Alitretinoin—Sweating—Epirubicin—peripheral nervous system neoplasm	2.87e-06	5.24e-05	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	2.87e-06	5.24e-05	CcSEcCtD
Alitretinoin—Haematuria—Epirubicin—peripheral nervous system neoplasm	2.85e-06	5.21e-05	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.85e-06	0.00103	CbGpPWpGaD
Alitretinoin—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	2.83e-06	5.18e-05	CcSEcCtD
Alitretinoin—Weight increased—Doxorubicin—peripheral nervous system neoplasm	2.82e-06	5.16e-05	CcSEcCtD
Alitretinoin—Epistaxis—Epirubicin—peripheral nervous system neoplasm	2.82e-06	5.15e-05	CcSEcCtD
Alitretinoin—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	2.81e-06	5.13e-05	CcSEcCtD
Alitretinoin—Sinusitis—Epirubicin—peripheral nervous system neoplasm	2.8e-06	5.13e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	2.8e-06	5.12e-05	CcSEcCtD
Alitretinoin—Nausea—Dactinomycin—peripheral nervous system neoplasm	2.79e-06	5.1e-05	CcSEcCtD
Alitretinoin—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	2.79e-06	5.1e-05	CcSEcCtD
Alitretinoin—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	2.78e-06	5.09e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	2.78e-06	5.08e-05	CcSEcCtD
Alitretinoin—Dizziness—Vincristine—peripheral nervous system neoplasm	2.78e-06	5.08e-05	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	2.77e-06	5.06e-05	CcSEcCtD
Alitretinoin—Infestation—Doxorubicin—peripheral nervous system neoplasm	2.77e-06	5.06e-05	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	2.77e-06	5.06e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.76e-06	0.000999	CbGpPWpGaD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	2.74e-06	5.01e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	2.74e-06	5e-05	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—peripheral nervous system neoplasm	2.72e-06	4.97e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—ERBB2—peripheral nervous system neoplasm	2.71e-06	0.000981	CbGpPWpGaD
Alitretinoin—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	2.71e-06	4.96e-05	CcSEcCtD
Alitretinoin—Urticaria—Etoposide—peripheral nervous system neoplasm	2.7e-06	4.94e-05	CcSEcCtD
Alitretinoin—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	2.7e-06	4.93e-05	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	2.7e-06	4.93e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Etoposide—peripheral nervous system neoplasm	2.69e-06	4.91e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Etoposide—peripheral nervous system neoplasm	2.69e-06	4.91e-05	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	2.69e-06	4.91e-05	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	2.69e-06	4.91e-05	CcSEcCtD
Alitretinoin—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	2.68e-06	4.91e-05	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—peripheral nervous system neoplasm	2.68e-06	4.91e-05	CcSEcCtD
Alitretinoin—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	2.67e-06	4.88e-05	CcSEcCtD
Alitretinoin—Vomiting—Vincristine—peripheral nervous system neoplasm	2.67e-06	4.88e-05	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.67e-06	0.000964	CbGpPWpGaD
Alitretinoin—Asthenia—Cisplatin—peripheral nervous system neoplasm	2.66e-06	4.87e-05	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	2.66e-06	4.87e-05	CcSEcCtD
Alitretinoin—Sweating—Doxorubicin—peripheral nervous system neoplasm	2.65e-06	4.85e-05	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	2.65e-06	4.84e-05	CcSEcCtD
Alitretinoin—Rash—Vincristine—peripheral nervous system neoplasm	2.65e-06	4.84e-05	CcSEcCtD
Alitretinoin—Dermatitis—Vincristine—peripheral nervous system neoplasm	2.65e-06	4.83e-05	CcSEcCtD
Alitretinoin—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	2.64e-06	4.83e-05	CcSEcCtD
Alitretinoin—Haematuria—Doxorubicin—peripheral nervous system neoplasm	2.64e-06	4.82e-05	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	2.63e-06	4.81e-05	CcSEcCtD
Alitretinoin—Headache—Vincristine—peripheral nervous system neoplasm	2.63e-06	4.81e-05	CcSEcCtD
Alitretinoin—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	2.61e-06	4.77e-05	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	2.6e-06	4.74e-05	CcSEcCtD
Alitretinoin—Visual impairment—Epirubicin—peripheral nervous system neoplasm	2.59e-06	4.73e-05	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	2.58e-06	4.72e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—BCHE—peripheral nervous system neoplasm	2.56e-06	0.000926	CbGpPWpGaD
Alitretinoin—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	2.54e-06	4.64e-05	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	2.54e-06	4.64e-05	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—peripheral nervous system neoplasm	2.51e-06	4.58e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	2.51e-06	4.58e-05	CcSEcCtD
Alitretinoin—Tinnitus—Epirubicin—peripheral nervous system neoplasm	2.5e-06	4.57e-05	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	2.5e-06	4.56e-05	CcSEcCtD
Alitretinoin—Nausea—Vincristine—peripheral nervous system neoplasm	2.49e-06	4.56e-05	CcSEcCtD
Alitretinoin—Flushing—Epirubicin—peripheral nervous system neoplasm	2.49e-06	4.55e-05	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	2.48e-06	4.54e-05	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	2.48e-06	4.54e-05	CcSEcCtD
Alitretinoin—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	2.47e-06	4.52e-05	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	2.46e-06	4.5e-05	CcSEcCtD
Alitretinoin—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	2.45e-06	4.48e-05	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	2.45e-06	4.47e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.44e-06	0.000883	CbGpPWpGaD
Alitretinoin—Asthenia—Etoposide—peripheral nervous system neoplasm	2.44e-06	4.46e-05	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—peripheral nervous system neoplasm	2.44e-06	4.45e-05	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	2.43e-06	4.45e-05	CcSEcCtD
Alitretinoin—Chills—Epirubicin—peripheral nervous system neoplasm	2.41e-06	4.4e-05	CcSEcCtD
Alitretinoin—Pruritus—Etoposide—peripheral nervous system neoplasm	2.41e-06	4.4e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—TH—peripheral nervous system neoplasm	2.41e-06	0.00087	CbGpPWpGaD
Alitretinoin—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	2.4e-06	4.38e-05	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	2.39e-06	4.37e-05	CcSEcCtD
Alitretinoin—Alopecia—Epirubicin—peripheral nervous system neoplasm	2.37e-06	4.33e-05	CcSEcCtD
Alitretinoin—Vomiting—Cisplatin—peripheral nervous system neoplasm	2.36e-06	4.31e-05	CcSEcCtD
Alitretinoin—Mental disorder—Epirubicin—peripheral nervous system neoplasm	2.35e-06	4.3e-05	CcSEcCtD
Alitretinoin—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	2.35e-06	4.29e-05	CcSEcCtD
Alitretinoin—Rash—Cisplatin—peripheral nervous system neoplasm	2.34e-06	4.28e-05	CcSEcCtD
Alitretinoin—Dermatitis—Cisplatin—peripheral nervous system neoplasm	2.34e-06	4.28e-05	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—peripheral nervous system neoplasm	2.34e-06	4.27e-05	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—peripheral nervous system neoplasm	2.34e-06	4.27e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Etoposide—peripheral nervous system neoplasm	2.33e-06	4.25e-05	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	2.32e-06	4.24e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.32e-06	0.000838	CbGpPWpGaD
Alitretinoin—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	2.32e-06	4.23e-05	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—peripheral nervous system neoplasm	2.3e-06	4.21e-05	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—peripheral nervous system neoplasm	2.3e-06	4.21e-05	CcSEcCtD
Alitretinoin—Tension—Epirubicin—peripheral nervous system neoplasm	2.29e-06	4.19e-05	CcSEcCtD
Alitretinoin—Nervousness—Epirubicin—peripheral nervous system neoplasm	2.27e-06	4.15e-05	CcSEcCtD
Alitretinoin—Back pain—Epirubicin—peripheral nervous system neoplasm	2.26e-06	4.13e-05	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	2.25e-06	4.12e-05	CcSEcCtD
Alitretinoin—Dizziness—Etoposide—peripheral nervous system neoplasm	2.25e-06	4.11e-05	CcSEcCtD
Alitretinoin—Chills—Doxorubicin—peripheral nervous system neoplasm	2.23e-06	4.07e-05	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	2.22e-06	4.05e-05	CcSEcCtD
Alitretinoin—Nausea—Cisplatin—peripheral nervous system neoplasm	2.21e-06	4.03e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.21e-06	0.000798	CbGpPWpGaD
Alitretinoin—Vision blurred—Epirubicin—peripheral nervous system neoplasm	2.2e-06	4.02e-05	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—peripheral nervous system neoplasm	2.19e-06	4.01e-05	CcSEcCtD
Alitretinoin—RARG—Gene Expression—MYC—peripheral nervous system neoplasm	2.19e-06	0.000793	CbGpPWpGaD
Alitretinoin—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	2.18e-06	3.98e-05	CcSEcCtD
Alitretinoin—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	2.17e-06	3.96e-05	CcSEcCtD
Alitretinoin—Vomiting—Etoposide—peripheral nervous system neoplasm	2.16e-06	3.95e-05	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	2.16e-06	3.95e-05	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—peripheral nervous system neoplasm	2.16e-06	3.95e-05	CcSEcCtD
Alitretinoin—Anaemia—Epirubicin—peripheral nervous system neoplasm	2.16e-06	3.95e-05	CcSEcCtD
Alitretinoin—Agitation—Epirubicin—peripheral nervous system neoplasm	2.15e-06	3.92e-05	CcSEcCtD
Alitretinoin—Rash—Etoposide—peripheral nervous system neoplasm	2.14e-06	3.92e-05	CcSEcCtD
Alitretinoin—Dermatitis—Etoposide—peripheral nervous system neoplasm	2.14e-06	3.92e-05	CcSEcCtD
Alitretinoin—Headache—Etoposide—peripheral nervous system neoplasm	2.13e-06	3.89e-05	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—peripheral nervous system neoplasm	2.13e-06	3.89e-05	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—peripheral nervous system neoplasm	2.12e-06	3.88e-05	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—peripheral nervous system neoplasm	2.11e-06	3.85e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.1e-06	0.000761	CbGpPWpGaD
Alitretinoin—Nervousness—Doxorubicin—peripheral nervous system neoplasm	2.1e-06	3.84e-05	CcSEcCtD
Alitretinoin—Syncope—Epirubicin—peripheral nervous system neoplasm	2.1e-06	3.83e-05	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—peripheral nervous system neoplasm	2.09e-06	3.82e-05	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.08e-06	0.000753	CbGpPWpGaD
Alitretinoin—Palpitations—Epirubicin—peripheral nervous system neoplasm	2.06e-06	3.77e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.06e-06	0.000746	CbGpPWpGaD
Alitretinoin—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	2.05e-06	3.75e-05	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	2.04e-06	0.000739	CbGpPWpGaD
Alitretinoin—Cough—Epirubicin—peripheral nervous system neoplasm	2.04e-06	3.73e-05	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	2.04e-06	3.72e-05	CcSEcCtD
Alitretinoin—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.02e-06	3.7e-05	CcSEcCtD
Alitretinoin—Nausea—Etoposide—peripheral nervous system neoplasm	2.02e-06	3.69e-05	CcSEcCtD
Alitretinoin—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.02e-06	3.69e-05	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—MYC—peripheral nervous system neoplasm	2.01e-06	0.000726	CbGpPWpGaD
Alitretinoin—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.01e-06	3.67e-05	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2e-06	3.65e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2e-06	0.000723	CbGpPWpGaD
Alitretinoin—Chest pain—Epirubicin—peripheral nervous system neoplasm	1.99e-06	3.64e-05	CcSEcCtD
Alitretinoin—Arthralgia—Epirubicin—peripheral nervous system neoplasm	1.99e-06	3.64e-05	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—peripheral nervous system neoplasm	1.99e-06	3.64e-05	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—peripheral nervous system neoplasm	1.99e-06	3.63e-05	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—peripheral nervous system neoplasm	1.98e-06	3.62e-05	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	1.98e-06	3.61e-05	CcSEcCtD
Alitretinoin—RARB—Gene Expression—MYC—peripheral nervous system neoplasm	1.97e-06	0.000712	CbGpPWpGaD
Alitretinoin—Discomfort—Epirubicin—peripheral nervous system neoplasm	1.97e-06	3.59e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—GNAS—peripheral nervous system neoplasm	1.96e-06	0.00071	CbGpPWpGaD
Alitretinoin—Malaise—Doxorubicin—peripheral nervous system neoplasm	1.95e-06	3.56e-05	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—peripheral nervous system neoplasm	1.95e-06	3.56e-05	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—peripheral nervous system neoplasm	1.94e-06	3.54e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—ABCB1—peripheral nervous system neoplasm	1.93e-06	0.000697	CbGpPWpGaD
Alitretinoin—Confusional state—Epirubicin—peripheral nervous system neoplasm	1.92e-06	3.51e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.92e-06	0.000693	CbGpPWpGaD
Alitretinoin—Palpitations—Doxorubicin—peripheral nervous system neoplasm	1.91e-06	3.49e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	1.91e-06	3.49e-05	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—peripheral nervous system neoplasm	1.91e-06	3.49e-05	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	1.9e-06	3.47e-05	CcSEcCtD
Alitretinoin—Infection—Epirubicin—peripheral nervous system neoplasm	1.89e-06	3.46e-05	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—peripheral nervous system neoplasm	1.89e-06	3.45e-05	CcSEcCtD
Alitretinoin—RXRB—Gene Expression—MYC—peripheral nervous system neoplasm	1.89e-06	0.000682	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—MYC—peripheral nervous system neoplasm	1.89e-06	0.000682	CbGpPWpGaD
Alitretinoin—Shock—Epirubicin—peripheral nervous system neoplasm	1.88e-06	3.43e-05	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—peripheral nervous system neoplasm	1.87e-06	3.42e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	1.87e-06	3.42e-05	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	1.87e-06	3.41e-05	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—peripheral nervous system neoplasm	1.87e-06	3.41e-05	CcSEcCtD
Alitretinoin—Tachycardia—Epirubicin—peripheral nervous system neoplasm	1.86e-06	3.4e-05	CcSEcCtD
Alitretinoin—Skin disorder—Epirubicin—peripheral nervous system neoplasm	1.85e-06	3.39e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.84e-06	0.000667	CbGpPWpGaD
Alitretinoin—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	1.84e-06	3.37e-05	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—peripheral nervous system neoplasm	1.84e-06	3.36e-05	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	1.84e-06	3.36e-05	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—peripheral nervous system neoplasm	1.84e-06	3.36e-05	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—peripheral nervous system neoplasm	1.83e-06	3.35e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.83e-06	0.000663	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	1.83e-06	3.34e-05	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—peripheral nervous system neoplasm	1.82e-06	3.32e-05	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—peripheral nervous system neoplasm	1.82e-06	3.32e-05	CcSEcCtD
Alitretinoin—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	1.8e-06	3.29e-05	CcSEcCtD
Alitretinoin—Hypotension—Epirubicin—peripheral nervous system neoplasm	1.78e-06	3.26e-05	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—peripheral nervous system neoplasm	1.78e-06	3.25e-05	CcSEcCtD
Alitretinoin—Oedema—Doxorubicin—peripheral nervous system neoplasm	1.76e-06	3.22e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	1.76e-06	3.22e-05	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—peripheral nervous system neoplasm	1.75e-06	3.2e-05	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—AKT1—peripheral nervous system neoplasm	1.75e-06	0.000633	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AKT1—peripheral nervous system neoplasm	1.75e-06	0.000633	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	1.74e-06	3.18e-05	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—peripheral nervous system neoplasm	1.74e-06	3.17e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	1.73e-06	3.16e-05	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	1.73e-06	3.16e-05	CcSEcCtD
Alitretinoin—Insomnia—Epirubicin—peripheral nervous system neoplasm	1.72e-06	3.15e-05	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	1.72e-06	3.15e-05	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	1.71e-06	3.13e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	1.71e-06	3.13e-05	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	1.71e-06	3.12e-05	CcSEcCtD
Alitretinoin—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	1.7e-06	3.11e-05	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—peripheral nervous system neoplasm	1.7e-06	3.1e-05	CcSEcCtD
Alitretinoin—Anorexia—Doxorubicin—peripheral nervous system neoplasm	1.68e-06	3.07e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	1.68e-06	3.07e-05	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.68e-06	0.000606	CbGpPWpGaD
Alitretinoin—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	1.66e-06	3.03e-05	CcSEcCtD
Alitretinoin—Hypotension—Doxorubicin—peripheral nervous system neoplasm	1.65e-06	3.01e-05	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	1.65e-06	3.01e-05	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.64e-06	3e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.64e-06	0.000594	CbGpPWpGaD
Alitretinoin—Pain—Epirubicin—peripheral nervous system neoplasm	1.63e-06	2.98e-05	CcSEcCtD
Alitretinoin—Constipation—Epirubicin—peripheral nervous system neoplasm	1.63e-06	2.98e-05	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.61e-06	2.94e-05	CcSEcCtD
Alitretinoin—Insomnia—Doxorubicin—peripheral nervous system neoplasm	1.6e-06	2.92e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.59e-06	0.000577	CbGpPWpGaD
Alitretinoin—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.58e-06	2.9e-05	CcSEcCtD
Alitretinoin—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.57e-06	2.87e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	1.57e-06	2.87e-05	CcSEcCtD
Alitretinoin—Somnolence—Doxorubicin—peripheral nervous system neoplasm	1.57e-06	2.87e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.56e-06	2.85e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.55e-06	2.84e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.53e-06	2.8e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.53e-06	0.000553	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.52e-06	2.78e-05	CcSEcCtD
Alitretinoin—RARG—Gene Expression—AKT1—peripheral nervous system neoplasm	1.52e-06	0.00055	CbGpPWpGaD
Alitretinoin—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.52e-06	2.78e-05	CcSEcCtD
Alitretinoin—Urticaria—Epirubicin—peripheral nervous system neoplasm	1.51e-06	2.77e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.51e-06	0.000546	CbGpPWpGaD
Alitretinoin—Pain—Doxorubicin—peripheral nervous system neoplasm	1.51e-06	2.76e-05	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—peripheral nervous system neoplasm	1.51e-06	2.76e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.51e-06	2.76e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.51e-06	2.76e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.47e-06	0.000532	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	1.45e-06	2.66e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.44e-06	2.64e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.4e-06	2.57e-05	CcSEcCtD
Alitretinoin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.4e-06	2.56e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.39e-06	2.55e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.39e-06	2.55e-05	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—AKT1—peripheral nervous system neoplasm	1.39e-06	0.000503	CbGpPWpGaD
Alitretinoin—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.37e-06	2.5e-05	CcSEcCtD
Alitretinoin—RARB—Gene Expression—AKT1—peripheral nervous system neoplasm	1.36e-06	0.000494	CbGpPWpGaD
Alitretinoin—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.35e-06	2.47e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.35e-06	0.000488	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.33e-06	0.000482	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—AKT1—peripheral nervous system neoplasm	1.31e-06	0.000473	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—AKT1—peripheral nervous system neoplasm	1.31e-06	0.000473	CbGpPWpGaD
Alitretinoin—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.3e-06	2.38e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.3e-06	2.38e-05	CcSEcCtD
Alitretinoin—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.27e-06	2.31e-05	CcSEcCtD
Alitretinoin—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.26e-06	2.3e-05	CcSEcCtD
Alitretinoin—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.25e-06	2.28e-05	CcSEcCtD
Alitretinoin—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.21e-06	2.22e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.21e-06	0.000438	CbGpPWpGaD
Alitretinoin—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.21e-06	2.21e-05	CcSEcCtD
Alitretinoin—Rash—Epirubicin—peripheral nervous system neoplasm	1.2e-06	2.2e-05	CcSEcCtD
Alitretinoin—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.2e-06	2.2e-05	CcSEcCtD
Alitretinoin—Headache—Epirubicin—peripheral nervous system neoplasm	1.19e-06	2.18e-05	CcSEcCtD
Alitretinoin—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.17e-06	2.13e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.14e-06	0.000412	CbGpPWpGaD
Alitretinoin—Nausea—Epirubicin—peripheral nervous system neoplasm	1.13e-06	2.07e-05	CcSEcCtD
Alitretinoin—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.12e-06	2.05e-05	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—peripheral nervous system neoplasm	1.11e-06	2.03e-05	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.11e-06	2.03e-05	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—peripheral nervous system neoplasm	1.11e-06	2.02e-05	CcSEcCtD
Alitretinoin—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.05e-06	1.92e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.02e-06	0.00037	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—MYC—peripheral nervous system neoplasm	9.83e-07	0.000356	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.75e-07	0.000353	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	9.66e-07	0.000349	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	9.61e-07	0.000348	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.16e-07	0.000295	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	7.85e-07	0.000284	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.79e-07	0.000282	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	7.67e-07	0.000278	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—AKT1—peripheral nervous system neoplasm	6.82e-07	0.000247	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.27e-07	0.000227	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.15e-07	0.000222	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AKT1—peripheral nervous system neoplasm	5.3e-07	0.000192	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.12e-07	7.66e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.69e-07	6.12e-05	CbGpPWpGaD
